ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0692

Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis

Miriam Retuerto Guerrero1, Clara Moriano2, cristiana sieiro santos3, Laura Sierra Herranz4, Javier Juan Garcia4, Ivan Castellvi Barranco5 and elvira Diez álvarez4, 1Complejo Asistencial Universitario de León, Leon, Spain, 2Hospital León, LEON, Spain, 3Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, 4Complejo Asistencial Universitario de Leon, Leon, 5Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, Clinical practice guidelines, interstitial lung disease, Scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is a common complication of systemic sclerosis (SSc) and is one of the leading causes of morbidity and mortality. Recently, several international associations (American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thorax Association (ALAT)) have joined forces and developed new international criteria for the diagnosis of progressive pulmonary fibrosis (PPF). We aim to identify the factors associated with the development of PPF, according to the new criteria of the ATS/ERS/JRS/ALAT societies, in patients with SSc-ILD.

Methods: A retrospective study of 51 patients with SSc-ILD diagnosed in the rheumatology department of the University Hospital Complex of León since the year 2000. Demographic, clinical, analytical, radiological, and pulmonary function variables were collected. The fulfillment of the new PPF criteria was evaluated, as well as their prognostic value. We compared clinical manifestations, antibody status, treatment, malignancy and death rates. Continuous variables were compared by Student’s or Mann Whitney’s test, and categorical variables by Chi2 test or Fisher’s exact test.

Results: Out of a total of 133 patients in our cohort, 51 patients with SSc-ILD were included, with 58.8% being women. The age at diagnosis of SSc and SSc-ILD was 59.2 ± 14.6 and 62.6 ± 14 years, respectively. 72.5% of the patients had limited cutaneous involvement and 45.1% were Anti-topoisomerase I positive. Tables 1 and 2 show the main clinical-serological and the morphological and functional pulmonary characteristics of our cohort. Twenty-two patients met the ATS/ERS/JRS/ALAT criteria over an 8.8 ± 7.3-year follow-up period from the diagnosis of SSc, representing 43.1% of the sample, with a mean time from the diagnosis of SSc-ILD of 36.7 ± 28.8 months. The proportion of patients with SSc-ILD who experienced progressive ILD during the first year was 17.6%, and 35.3% at five years. Smoking habits (p 0.010), younger age at diagnosis of SSc-ILD (p 0.049) and ESR levels (p 0.005) are independent factors for the presence of PPF (Table 3). No relationship was observed with sex or the different characteristics of the disease. Greater initial radiological involvement (extent by HRCT >20%, p 0.013) and functional impairment (%FVC, p 0.022; %DLCO, p 0.007) were related to the development of PPF. The use of corticosteroids (p 0.005), CYC (p 0.034), RTX (p 0.039) and Ninte (p 0.011) was higher in patients with PPF. Similarly, they received more combined therapeutic strategies (p 0.010). During follow-up, 14 patients died, 7 of them from complications related to ILD, with a higher incidence in progressive patients (27.3% vs. 3.4%, p 0.034).

Conclusion: Almost half of our cohort meets the criteria for PPF according to ATS/ERS/JRS/ALAT criteria. These patients present greater pulmonary involvement at diagnosis and higher pulmonary-related mortality.

Supporting image 1

Table 1. Clinical-serological variables of the 51 patients with SSc-ILD.

Supporting image 2

Table 2. Morphological and functional pulmonary characteristics of our SSc-ILD cohort.

Supporting image 3

Table 3. Clinical-serological characteristics of our SSc-ILD cohort, differences between patients who meet ATS/ERS/JRS/ALAT progression criteria and those who do not.


Disclosures: M. Retuerto Guerrero: None; C. Moriano: None; c. sieiro santos: None; L. Sierra Herranz: None; J. Juan Garcia: None; I. Castellvi Barranco: None; e. Diez álvarez: None.

To cite this abstract in AMA style:

Retuerto Guerrero M, Moriano C, sieiro santos c, Sierra Herranz L, Juan Garcia J, Castellvi Barranco I, Diez álvarez e. Evaluation of the New Criteria for Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-the-new-criteria-for-progressive-pulmonary-fibrosis-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-the-new-criteria-for-progressive-pulmonary-fibrosis-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology